Biopharma Watch: Rhythm Pharmaceuticals Crushes Q4 Estimates as Incannex Healthcare Shows Late-Day Strength
Rhythm Pharmaceuticals (RYTM) delivered a surprisingly robust financial performance for the fourth quarter of 2025. The company reported an EPS of -$0.73, comfortably…
